Urovant Sciences Ltd. (UROV) Stock: Is This Biotechnology Stock Worth Your Time?


Urovant Sciences Ltd. (UROV) is trending down in the market today. The company, focused in the biotechnology industry, is presently trading at $11.22 after a move down of -19.05% so far in today’s session. In terms of biotech companies, there are a number of aspects that have the ability to lead to declines in the market. News is one of the most common reasons for movement. Here are the recent headlines associated with UROV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 08:00AM Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Mar-18-19 04:05PM Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
Mar-07-19 08:00AM Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
Mar-06-19 08:00AM Urovant Sciences Appoints James Robinson to its Board of Directors
Feb-26-19 08:14PM Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript

However, any time investors are making an investing decision, prospective investors should focus on far more than news, this is especially the case in the highly speculative biotechnology industry. Here’s what’s happening in regard to Urovant Sciences Ltd..

The Performance That UROV Investors Have Experienced

While a decline in a single session, like the move that we’re seeing from Urovant Sciences Ltd. might lead to fear in some investors, a single session decline by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It is always a good idea to look at trends further out than a single trading session. As it relates to UROV, here are the movements that we have seen:

  • Past 7 Days – Over the past week, UROV has produced a price change amounting to 4.76%.
  • Past 30 Days – The monthly performance from Urovant Sciences Ltd. has been 32.00%.
  • Quarterly – In the last three months, the company has generated a return that works out to 131.00%
  • Past Six Months – In the last 6 months, we’ve seen a change of 0 from the company.
  • YTD – Since the open of this year UROV has generated a return on investment of 110.32%.
  • Full Year – Finally, in the last year, we’ve seen a change amounting to 0 from UROV. Throughout this period of time, the stock has sold at a high price of -22.57% and a low price of 176.70%.

Ratios To Watch

Looking at a few ratios associated with a company can provide investors an understanding of how risky and/or rewarding a an investment option might be. Below are some of the important ratios to look at when digging into UROV.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is going to go down. Across the sector, biotech stocks tend to have a higher short ratio. However, we also see a lot of short squeezes in the industry. Nonetheless, with regard to Urovant Sciences Ltd., it’s short ratio is 0.70.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure If a company is able to pay its debts when they come due with only current assets or quick assets. In the biotechnology sector, many companies are heavily reliant on the continuation of investor support, the current and quick ratios can seem damning. However, several gems in the biotech sector come with strong current and quick ratios. In terms of UROV, the quick and current ratios add up to 11.00 and 11.00 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price of the stock. In this case, that ratio is 3.38.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. In this case, the cash to share value ratio comes to 3.23.

What Analysts Say About Urovant Sciences Ltd.

Although it’s rarely a smart idea to blindly follow the thoughts of analysts, it is a smart idea to consider their opinions when validating your own before making investment decisions in the biotech space. Here are the most recent moves that we have seen from analysts as it relates to UROV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 Initiated SunTrust Buy $24
Mar-11-19 Initiated H.C. Wainwright Buy $28
Oct-22-18 Initiated JP Morgan Overweight $21
Oct-22-18 Initiated Jefferies Buy $19

Is Big Money Interested in Urovant Sciences Ltd.?

One thing that I’ve learned in my short period on Earth is that smart money tends to follow the moves made by big money. In other words, investors that are trying to play it relatively safe will pay close attention to moves made by institutions and those on the inside. With that said, is big money interested as it relates to UROV? Here’s the information:

Institutions own 22.80% of the company. Institutional interest has moved by -2.22% over the past three months. When it comes to insiders, those who are close to the company currently own 74.90% percent of UROV shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s The Float Looking Like?

Traders seem to like to know the counts of shares both outstanding and available. In regard to Urovant Sciences Ltd., currently there are 29.57M and there is a float of 7.62M. These data mean that of the total of 29.57M shares of UROV currently in existence today, 7.62M are available to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to UROV, the short percent of the float is 0.43%.

What We’ve Seen In Financial Results

What have ween seen from UROV in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands, Wall Street analysts are expecting that UROV will create EPS of -3.96, with -0.92 to be announced in the report for the current quarter. Although this data is not associated with earnings, because we’re chatting on the topic of Wall Street analysts, Urovant Sciences Ltd. is currently graded as a 1.80 when rated on a scale from 1 to 5 on which 1 is the poorest Wall St. analyst grade and 5 is the best.
  • 5-Year Sales – In the past 5 years, Urovant Sciences Ltd. has created a change in sales volume that adds up to 0. Earnings in the period have seen a change of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is generally represented in the human world, Urovant Sciences Ltd. has created a change in earnings that comes to a total of -85.10%. Urovant Sciences Ltd. has also seen movement with regard to sales volume that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, based on what I am, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here